FY2030 Earnings Estimate for ACHV Issued By HC Wainwright

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Equities researchers at HC Wainwright issued their FY2030 earnings estimates for Achieve Life Sciences in a note issued to investors on Monday, January 26th. HC Wainwright analyst B. Folkes anticipates that the biopharmaceutical company will post earnings of $1.64 per share for the year. The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share.

Achieve Life Sciences (NASDAQ:ACHV) last released its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04).

Several other equities analysts have also recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Achieve Life Sciences in a research report on Monday, December 29th. Citizens Jmp assumed coverage on Achieve Life Sciences in a report on Tuesday, November 25th. They set a “market outperform” rating and a $19.00 target price for the company. Raymond James Financial reiterated a “strong-buy” rating on shares of Achieve Life Sciences in a research report on Monday, November 24th. Finally, Citigroup started coverage on shares of Achieve Life Sciences in a research report on Tuesday, November 25th. They issued an “outperform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $15.50.

Achieve Life Sciences Trading Down 5.4%

NASDAQ:ACHV opened at $4.36 on Tuesday. The company has a market cap of $232.08 million, a P/E ratio of -3.16 and a beta of 1.71. The stock’s fifty day moving average price is $4.85 and its two-hundred day moving average price is $3.89. Achieve Life Sciences has a 1 year low of $1.84 and a 1 year high of $6.03. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.14 and a quick ratio of 5.14.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Franklin Resources Inc. boosted its holdings in Achieve Life Sciences by 81.3% during the 2nd quarter. Franklin Resources Inc. now owns 4,459,014 shares of the biopharmaceutical company’s stock valued at $10,077,000 after acquiring an additional 2,000,079 shares during the period. Simplify Asset Management Inc. lifted its position in Achieve Life Sciences by 443.7% in the second quarter. Simplify Asset Management Inc. now owns 1,184,512 shares of the biopharmaceutical company’s stock valued at $2,677,000 after purchasing an additional 966,667 shares during the last quarter. Stonepine Capital Management LLC bought a new position in shares of Achieve Life Sciences in the second quarter worth approximately $753,000. Highbridge Capital Management LLC purchased a new position in shares of Achieve Life Sciences in the second quarter worth $300,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in Achieve Life Sciences during the 2nd quarter valued at $263,000. 33.52% of the stock is currently owned by institutional investors.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.